Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Thorac Cancer. 2018 Jun;9(6):745-749. doi: 10.1111/1759-7714.12637. Epub 2018 Apr 19.
The most common EGFR mutations in non-small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to EGFR-tyrosine kinase inhibitors. However, rare EGFR mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239-2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. Herein, possible correlations between gene analysis and the outcomes of subsequent treatment are discussed.
非小细胞肺癌中最常见的 EGFR 突变是外显子 19 缺失和外显子 21 点突变，这两者均对 EGFR-酪氨酸激酶抑制剂敏感。然而，确实存在罕见的 EGFR 突变，并且这些突变对酪氨酸激酶抑制剂的反应尚不清楚。一名被诊断为 IV 期肺腺癌的中国女性携带有罕见的 EGFR L747P（2239-2240 TT > CC）突变，吉非替尼和奥希替尼治疗未能达到预期效果。在此，讨论了基因分析与后续治疗结果之间可能存在的相关性。
